Cure My Disease

Don't miss your cure!

 Log in / Sign up

Engineered killer cells take on Hard-to-Treat lymphoma

NCT ID NCT06334991

Ongoing Disease control Sponsor: ImmunityBio, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jul 10, 2026 · Updated 2 times

Summary

This early-phase trial is testing a new therapy called CD19 t-haNK, which uses specially engineered natural killer cells to target and destroy cancer cells. It is being tested alone and with the drug rituximab in 10 adults with B-cell non-Hodgkin lymphoma that has come back or not responded to prior treatments. The main goal is to check safety, but researchers will also look at how well the tumors shrink.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
CD19 t-haNK (an engineered natural killer cell therapy) and rituximab
What this could lead to
If successful, this could point toward a new treatment option for people with B-cell non-Hodgkin lymphoma that has not responded to standard therapies.
What could go wrong
This is a very early, small Phase 1 trial with only 10 participants, so results may not apply broadly. The main goal is safety, not yet proof of effectiveness, and there are risks like infusion reactions or cytokine release syndrome.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-HODGKIN LYMPHOMA REFRACTORY/ RELAPSED are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell non-Hodgkin lymphoma non-Hodgkin lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-HODGKIN LYMPHOMA REFRACTORY/ RELAPSED

Contacts and locations

Locations

  • Albert Cellular Therapy

    Pretoria, Gauteng, 0044, South Africa

  • Dr. Jackie Thomson Inc.

    Johannesburg, Gauteng, 2193, South Africa

  • FARMOVS

    Bloemfontein, Free State, 9301, South Africa

More trials for these conditions

Other studies related to the condition(s) this trial covers.